niraparib (zejula) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Niraparib (MK-4827) displays excellent PARP 1 and 2 inhibition. Inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells. Niraparib is in development with TESARO, under licence from Merck & Co, for the treatment of cancers (ovarian, fallopian tube and peritoneal cancer, breast cancer, prostate cancer and Ewing's sarcoma). Niraparib was characterized in a number of preclinical models before moving to phase I clinical trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients. It is currently being tested in phase 3 clinical trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer.   NCATS

  • SMILES: O.Cc1ccc(cc1)S(=O)(=O)[O-].NC(=O)c2cccc3cn(nc23)c4ccc(cc4)[C@@H]5CCC[NH2+]C5
  • Mol. Mass: 510.62
  • ALogP: 2.59
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$173.6263 - $226.1553
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide | mk4827 | mk 4827 | mk-4827 | niraparib | niraparib hydrochloride | niraparib tosylate | niraparib tosylate monohydrate | zejula


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue